Caribou Biosciences, Inc.
CRBU · XNASCIK 1619856fmd_16NCQKWF8DBQ2KZ1VXVRPJBSVMManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 29 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 6 | 12 | 10 | 14 | 34 | 10 | 11 |
| Research and development | 24 | 34 | 52 | 82 | 112 | 130 | 109 |
| Total operating expenses | 40 | 48 | 77 | 120 | 151 | 177 | 160 |
| Operating income | (34) | (36) | (67) | (106) | (116) | (167) | (148) |
| Interest expense | 0 | 0 | 0 | – | – | – | – |
| Other non-operating income (expense) | 3 | (0) | 0 | 7 | 14 | 18 | (0) |
| Income before taxes | (31) | (36) | (67) | (99) | (102) | (149) | (149) |
| Income tax expense | (8) | (2) | 0 | 0 | 0 | (0) | (1) |
| Net income from continuing operations | (23) | (34) | (67) | (99) | (102) | (149) | (148) |
| Net income | (23) | (34) | (67) | (99) | (102) | (149) | (148) |